555 related articles for article (PubMed ID: 10606188)
61. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
62. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.
Waber PG; Chen J; Nisen PD
Cancer Res; 1993 Dec; 53(24):6028-30. PubMed ID: 8261417
[TBL] [Abstract][Full Text] [Related]
63. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
[TBL] [Abstract][Full Text] [Related]
64. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
65. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
[TBL] [Abstract][Full Text] [Related]
66. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
67. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
68. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R
Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701
[TBL] [Abstract][Full Text] [Related]
69. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
[TBL] [Abstract][Full Text] [Related]
70. Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas.
Oda Y; Schneider-Stock R; Ryś J; Gruchała A; Niezabitowski A; Roessner A
Diagn Mol Pathol; 1996 Jun; 5(2):98-106. PubMed ID: 8727096
[TBL] [Abstract][Full Text] [Related]
71. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970
[TBL] [Abstract][Full Text] [Related]
72. Tumor suppressor genes and related molecules in leiomyosarcoma.
Dei Tos AP; Maestro R; Doglioni C; Piccinin S; Libera DD; Boiocchi M; Fletcher CD
Am J Pathol; 1996 Apr; 148(4):1037-45. PubMed ID: 8644845
[TBL] [Abstract][Full Text] [Related]
73. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
74. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
75. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
76. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas.
Rieske P; Kordek R; Bartkowiak J; Debiec-Rychter M; Biernat W; Liberski PP
Pol J Pathol; 1998; 49(3):145-9. PubMed ID: 9810172
[TBL] [Abstract][Full Text] [Related]
77. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
78. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
79. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor.
Kawai A; Noguchi M; Beppu Y; Yokoyama R; Mukai K; Hirohashi S; Inoue H; Fukuma H
Cancer; 1994 May; 73(10):2499-505. PubMed ID: 8174045
[TBL] [Abstract][Full Text] [Related]
80. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]